Kancera AB, a biotechnology company, engages in the development and sale of pharmaceutical drug candidates in Sweden. The company develops drugs for the treatment of leukemia and solid tumors based on blocking survival signals in the cancer cell and on preventing adaptation of the cancer’s metabolism. Its pharmaceutical development projects include ROR inhibitors that reprogram the cancer cells, which are drug candidates for treatment of leukemia and solid tumors; PFKFB inhibitors for reducing cancer’s energy supply from glucose to solid tumors; HDAC6 inhibitors that are aimed to neutralize blood cancer by controlling the cancer cell genome; and AZD8797, fractalkine inhibitor for stopping the tumor growth and relieve severe pain, as well as small molecule inhibitors of epigenetic processes in parasites for the development of new treatments, including malaria and schistosomiasis. The company’s customers include pharmaceutical and biotechnology companies. Kancera AB was founded in 2010 and is based in Solna, Sweden.
kancera ab (KAN:Stockholm)
Karolinska Institutet Science Park
Solna, 171 48
Phone: 46 8 50 12 60 80
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for KAN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact KANCERA AB, please visit www.kancera.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.